EA201990388A1 - Пиперидиновые модуляторы рецепторов cxcr7 - Google Patents

Пиперидиновые модуляторы рецепторов cxcr7

Info

Publication number
EA201990388A1
EA201990388A1 EA201990388A EA201990388A EA201990388A1 EA 201990388 A1 EA201990388 A1 EA 201990388A1 EA 201990388 A EA201990388 A EA 201990388A EA 201990388 A EA201990388 A EA 201990388A EA 201990388 A1 EA201990388 A1 EA 201990388A1
Authority
EA
Eurasian Patent Office
Prior art keywords
modulators
cxcr7
piperidine
formula
pharmaceuticals
Prior art date
Application number
EA201990388A
Other languages
English (en)
Other versions
EA037507B1 (ru
Inventor
Хамед Айссауи
Филипп Герри
Франсуа Леамбр
Жюльен Потье
Летиция Пузоль
Сильвия Рихард-Бильдштайн
Шугуан Юань
Original Assignee
Идорсия Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Идорсия Фармасьютиклз Лтд filed Critical Идорсия Фармасьютиклз Лтд
Publication of EA201990388A1 publication Critical patent/EA201990388A1/ru
Publication of EA037507B1 publication Critical patent/EA037507B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Abstract

Настоящее изобретение относится к пиперидиновым производным формулы (I)где Ar, Ar, R, R, Rи Rимеют значения, указанные в описании, к их получению, к их фармацевтически приемлемым солям и к их применению в качестве фармацевтических препаратов, к фармацевтическим композициям, которые содержат одно или несколько соединений формулы (I) и в особенности к их применению в качестве модуляторов рецепторов CXCR7.
EA201990388A 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7 EA037507B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016068052 2016-07-28
PCT/EP2017/068990 WO2018019929A1 (en) 2016-07-28 2017-07-27 Piperidine cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
EA201990388A1 true EA201990388A1 (ru) 2019-08-30
EA037507B1 EA037507B1 (ru) 2021-04-06

Family

ID=59656027

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990388A EA037507B1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7
EA202091262A EA202091262A1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202091262A EA202091262A1 (ru) 2016-07-28 2017-07-27 Пиперидиновые модуляторы рецепторов cxcr7

Country Status (32)

Country Link
US (2) US10752620B2 (ru)
EP (2) EP3798217B1 (ru)
JP (2) JP6655754B2 (ru)
KR (2) KR102497095B1 (ru)
CN (2) CN109563085B (ru)
AR (2) AR109180A1 (ru)
AU (2) AU2017302079B2 (ru)
BR (1) BR112019001551A2 (ru)
CA (1) CA3032017C (ru)
CL (2) CL2019000169A1 (ru)
CY (1) CY1125016T1 (ru)
DK (2) DK3490986T3 (ru)
EA (2) EA037507B1 (ru)
ES (2) ES2954152T3 (ru)
FI (1) FI3798217T3 (ru)
HR (2) HRP20211988T1 (ru)
HU (2) HUE057315T2 (ru)
IL (2) IL264424B (ru)
LT (2) LT3798217T (ru)
MA (2) MA54653B1 (ru)
MX (2) MX2019001042A (ru)
MY (1) MY198113A (ru)
NZ (1) NZ751006A (ru)
PH (1) PH12019500188A1 (ru)
PL (2) PL3490986T3 (ru)
PT (2) PT3490986T (ru)
RS (2) RS64130B1 (ru)
SG (2) SG10201906942PA (ru)
SI (2) SI3798217T1 (ru)
TW (3) TWI683812B (ru)
WO (1) WO2018019929A1 (ru)
ZA (1) ZA201901256B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502046B1 (ko) * 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태
KR20220093330A (ko) 2019-10-31 2022-07-05 이도르시아 파마슈티컬스 리미티드 Cxcr7 안타고니스트와 s1p1 수용체 조절인자의 조합
WO2023012044A1 (en) 2021-08-02 2023-02-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
CN117396471A (zh) * 2021-10-01 2024-01-12 株式会社次代生物科学 新的哌啶衍生物和包含其的用于抑制自分泌运动因子的药物组合物
WO2023110871A1 (en) 2021-12-17 2023-06-22 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
EP4238970A1 (en) 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
EP2431357A3 (en) 2002-11-27 2012-08-22 Incyte Corporation 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
WO2005032490A2 (en) 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
AU2006215399B2 (en) 2005-02-18 2010-12-09 Astrazeneca Ab Antibacterial piperidine derivatives
CA2742515C (en) * 2008-11-04 2017-07-11 Chemocentryx, Inc. 1,4-diazepane modulators of cxcr7
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
WO2013084241A1 (en) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
RU2649004C2 (ru) * 2012-11-29 2018-03-29 Кемосентрикс, Инк. Антагонисты cxcr7
CA2912133C (en) 2013-05-30 2021-06-22 Actelion Pharmaceuticals Ltd Cxcr7 receptor modulators
AU2014315457B2 (en) 2013-09-04 2018-05-10 Bristol-Myers Squibb Company Compounds useful as immunomodulators
PT3363790T (pt) 2013-09-06 2020-05-06 Aurigene Discovery Tech Ltd Derivados 1,2,4-oxadiazoles como imunomoduladores
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
MX2017002986A (es) * 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
EP3227263B1 (en) 2014-12-01 2019-04-10 Idorsia Pharmaceuticals Ltd Cxcr7 receptor modulators
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Also Published As

Publication number Publication date
PL3490986T3 (pl) 2022-04-04
CY1125016T1 (el) 2023-03-24
IL264424A (en) 2019-02-28
CA3032017A1 (en) 2018-02-01
KR20200092420A (ko) 2020-08-03
TWI691497B (zh) 2020-04-21
MX2021004000A (es) 2021-06-23
KR102497091B1 (ko) 2023-02-06
DK3490986T3 (da) 2022-03-07
EP3798217A1 (en) 2021-03-31
US20200385373A1 (en) 2020-12-10
ES2954152T3 (es) 2023-11-20
CA3032017C (en) 2023-04-18
SI3490986T1 (sl) 2022-02-28
JP6655742B2 (ja) 2020-02-26
JP6655754B2 (ja) 2020-02-26
EP3798217B1 (en) 2023-02-22
KR102497095B1 (ko) 2023-02-06
MA45782B1 (fr) 2021-12-31
US10752620B2 (en) 2020-08-25
CL2019003281A1 (es) 2020-05-04
AU2017302079A1 (en) 2019-03-21
RS62855B1 (sr) 2022-02-28
TWI683812B (zh) 2020-02-01
SG11201900633XA (en) 2019-02-27
MX2019001042A (es) 2019-06-10
MA45782A (fr) 2019-06-05
NZ751006A (en) 2021-07-30
US11306078B2 (en) 2022-04-19
TWI691494B (zh) 2020-04-21
TW201932454A (zh) 2019-08-16
AU2020204578A1 (en) 2020-07-30
DK3798217T3 (da) 2023-05-22
MA54653B1 (fr) 2023-04-28
EP3490986B1 (en) 2021-11-24
AR115662A2 (es) 2021-02-10
SI3798217T1 (sl) 2023-05-31
CN109563085A (zh) 2019-04-02
RS64130B1 (sr) 2023-05-31
CN110563717B (zh) 2022-08-09
EA202091262A1 (ru) 2020-08-13
HUE062019T2 (hu) 2023-09-28
ES2905755T3 (es) 2022-04-12
PH12019500188A1 (en) 2019-10-21
CN110563717A (zh) 2019-12-13
PT3490986T (pt) 2022-02-01
LT3490986T (lt) 2022-02-10
PL3798217T3 (pl) 2023-06-12
IL282942A (en) 2021-06-30
US20190169180A1 (en) 2019-06-06
IL264424B (en) 2021-08-31
FI3798217T3 (fi) 2023-05-03
IL282942B (en) 2022-01-01
HUE057315T2 (hu) 2022-04-28
SG10201906942PA (en) 2019-09-27
CL2019000169A1 (es) 2019-06-21
HRP20230313T1 (hr) 2023-05-12
TW201806940A (zh) 2018-03-01
KR20190034620A (ko) 2019-04-02
WO2018019929A1 (en) 2018-02-01
CN109563085B (zh) 2022-08-09
PT3798217T (pt) 2023-05-23
BR112019001551A2 (pt) 2019-05-14
HRP20211988T1 (hr) 2022-03-18
MY198113A (en) 2023-08-03
JP2019142874A (ja) 2019-08-29
MA54653A (fr) 2021-12-29
AR109180A1 (es) 2018-11-07
EP3490986A1 (en) 2019-06-05
AU2020204578B2 (en) 2022-03-10
LT3798217T (lt) 2023-05-25
ZA201901256B (en) 2021-08-25
EA037507B1 (ru) 2021-04-06
TW201922738A (zh) 2019-06-16
JP2019525927A (ja) 2019-09-12
AU2017302079B2 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201891179A1 (ru) N-замещенные индольные производные в качестве модуляторов pge2 рецепторов
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201992679A1 (ru) N-замещенные индольные производные
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201501163A1 (ru) Модуляторы рецептора cxcr7
PH12018500377A1 (en) Novel annelated benzamides
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
EA201691673A1 (ru) Замещенные циклопентаны, тетрагидрофураны и пирролидины как антагонисты орексиновых рецепторов
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM